Biotech Values

[isolution]

OXGN interim results


While instances of hypertension were noted in the Phase I/II study by Dr. Campochiaro, he indicated that a local method of delivery could substantially reduce systemic exposure to CA4P and further improve its safety profile in this clinical setting. [Translation: CA4P is probably too toxic for *systemic* treatment in AMD]

I agree dew and it also makes a rationale with their choice of conducting a clinical trial on patients having myopic macular degeneration [Translation: young population of patients - about 40 years old - less prone to have cardiac problems]

Regards